Tumor Treating Fields Therapy

PROCEDURE6 trials

Sponsors

M.D. Anderson Cancer Center, Sidney Kimmel Cancer Center at Thomas Jefferson University, OHSU Knight Cancer Institute, Mayo Clinic, Emory University

Conditions

Advanced Breast CarcinomaAdvanced Endometrial CarcinomaAdvanced Fallopian Tube CarcinomaAdvanced Hepatocellular CarcinomaAdvanced Malignant Abdominal NeoplasmAdvanced Malignant Female Reproductive System NeoplasmAdvanced Malignant NeoplasmAdvanced Malignant Thoracic Neoplasm

Early Phase 1

Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma

CompletedNCT03477110

Sidney Kimmel Cancer Center at Thomas Jefferson UniversityGlioblastoma

Start: 2018-05-04End: 2024-01-26Updated: 2025-05-15

Phase 1

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

Active, not recruitingNCT03203525

M.D. Anderson Cancer CenterAdvanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver, Metastatic Malignant Neoplasm in the Liver +1

Start: 2020-06-23End: 2026-12-31Updated: 2026-02-25

Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial

RecruitingNCT05030298

Mayo ClinicMalignant Glioma

Start: 2023-05-23End: 2027-09-15Target: 28Updated: 2025-11-21

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

RecruitingNCT05092373

M.D. Anderson Cancer CenterAdvanced Breast Carcinoma, Advanced Endometrial Carcinoma, Advanced Fallopian Tube Carcinoma +71

Start: 2022-04-29End: 2026-09-01Target: 43Updated: 2026-01-14

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

Active, not recruitingNCT05341349

Emory UniversityClinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in the Brain +4

Start: 2022-10-13End: 2027-03-06Updated: 2025-07-30

Phase 2

Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer

TerminatedNCT03995667

OHSU Knight Cancer InstituteExtensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Stage IA1 Lung Cancer AJCC v8 +14

Start: 2019-06-11End: 2022-08-04Updated: 2023-10-30

Related Papers

1047 Preoperative Stereotactic Radiosurgery Positively Modulates the Tumor Immune Microenvironment in Glioblastoma: Preliminary Findings of a Phase I/IIa Human Clinical Trial

Neurosurgery2025-03-14

Case report: durable response of gliomatosis cerebri with concurrent tumor-treating fields (TTFields) and chemoradiotherapy treatment.

2023-12-011 citations

Molecular markers impacting survival in patients receiving concurrent chemoradiation and Tumor-Treating Fields (TTF) in patients with newly diagnosed glioblastoma: secondary analysis of SPARE trial (P13-13.003)

Neurology2023-04-25

Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot study.

2022-11-1013 citations

RADT-19. CHEMORADIATION (CRT) TREATMENT WITH OR WITHOUT CONCURRENT TUMOR-TREATING FIELDS (TTFIELDS) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)

Neuro-Oncology2022-11-01

INNV-09. IMPACT OF MOLECULAR MARKERS ON TREATMENT OUTCOME OF GLIOBLASTOMA PATIENTS TREATED WITH CONCURRENT TUMOR-TREATING FIELDS (TTF) AND CHEMORADIATION: SECONDARY ANALYSIS OF SPARE TRIAL

Neuro-Oncology2022-11-01

Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma

Frontiers in Oncology2022-04-2929 citations

CTNI-19. CONCURRENT CHEMORADIATION AND TUMOR TREATING FIELDS (TTFields, 200 kHz) FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MAY INCREASE THE RATE OF DISTANT RECURRENCE

Neuro-Oncology2021-11-02

RADT-22. CONCURRENT TTFIELDS (200 KHZ) WITH CHEMORADIATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MAY INCREASE THE RATE OF PSEUDOPROGRESSION: ANALYSIS OF A PILOT CLINICAL TRIAL

Neuro-Oncology2021-11-02

Concurrent TTFields (200 kHz) With Chemoradiation for Patients With Newly Diagnosed Glioblastoma May Increase the Rate of Pseudoprogression: Analysis of a Pilot Clinical Trial.

2021-11-01

Concurrent Chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for Patients With Newly Diagnosed Glioblastoma May Increase the Rate of Distant Recurrence.

2021-11-01

Scalp-sparing radiation with concurrent temozolomide and tumor treating fields (SPARE) for patients with newly diagnosed glioblastoma.

Journal of Clinical Oncology2021-05-204 citations

CTNI-21. SCALP SPARING RADIATION WITH CONCURRENT TEMOZOLOMIDE AND TUMOR TREATMENT FIELDS (SPARE) FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

Neuro-Oncology2020-11-01

Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma.

2020-03-2321 citations